Table 1.

Demographic information for TOL patients and SI patients, and varying kidney function used for novel discovery (stage 1), qPCR validation (stage 2), and TOL modeling (stage 3) (n=121 unique patients)

VariableTOL (n=43)aSI (n=78)a
 Male patients (%)68.4%74.0%
 Mean age±SD (yr)28±2015±13
 Race (%)
  African American022
 Post-transplant time (mo)
 Induction therapyNADaclizumab/antithymocyte globulin
 Maintenance therapyCNI+steroids/MMF, with or without AZA
 Serum creatinine (mg/dl)0.95±0.22.92±2.9
 LRD donor source (%)0.320.67
 Mean HLA mismatch (x/6) ±SD0.75±1.52.92±2.9
 Male donors (%)0.50.42
 Mean age±SD (yr)39.8±16.642.86±10.84
  • NA, not applicable; CNI, calcineurin inhibitor (cyclosporine, tacrolimus); MMF, mycophenolate mofetil; AZA, azathioprine; LRD, living-related donor; x/6, number of HLA mismatches out of a total of 6.

  • a Unique patients used in novel microarray discovery; qPCR validation and modeling.